drugset / Trial / NCT02138747
A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
RandomizedCrossoverDouble-blindTreatment
Summary
The purpose of this study was to assess tolerability of mirabegron compared to tolterodine ER in the treatment of participants with symptoms of Overactive Bladder (OAB) as well as the impact of treatment on micturition frequency and incontinence episodes.
Timeline
- Start
- 2014-07-24
- Primary completion
- 2015-10-29
- Completion
- 2015-11-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirabegron | Other / unclassified | 50 mg | Oral |
| Subject | Tolterodine | Small molecule | 4 mg | Oral |